Amanda J Wade

Dr. Amanda J Wade


Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 November 2015 in PLOS ONE
Verified
Journal Article
Open access
PDF file
AWAmanda J Wade
Amanda J Wade
DMDiana M Macdonald
Diana M Macdonald
JDJoseph Doyle
Joseph Doyle
AGAdam Gordon
Adam Gordon
SRStuart K Roberts
Stuart K Roberts
MHMargaret E Hellard
Margaret E Hellard
Hepatitis C treatment uptake in Australia is low. To increase access to hepatitis C virus treatment for people who inject drugs, we developed a community-based, nurse-led service that linked a viral hepatitis service in a tertiary hospital to primary care clinics, and resulted in hepatitis C treatment provision in the community. A retrospective cohort study of patients referred to the community hepatitis service was undertaken to determine the cascade of care. Logistic regression analyses were used to identify predictors of hepatitis C treatment uptake. Four hundred and sixty-two patients were referred to the community hepatitis service; 344 attended. Among the 279 attendees with confirmed chronic hepatitis C, 257 (99%) reported ever injecting drugs, and 124 (48%) injected in the last month. Of 201 (72%) patients who had their fibrosis staged, 63 (31%) had F3-F4 fibrosis. Fifty-five patients commenced hepatitis C treatment; 26 (47%) were current injectors and 25 (45%) had F3-F4 fibrosis. Nineteen of the 27 (70%) genotype 1 patients and 14 of the 26 (54%) genotype 3 patients eligible for assessment achieved a sustained virologic response. Advanced fibrosis was a significant predictor of treatment uptake in adjusted analysis (AOR 2.56, CI 1.30–5.00, p = 0.006). Our community hepatitis service produced relatively high rates of fibrosis assessment, hepatitis C treatment uptake and cure, among people who inject drugs. These findings highlight the potential benefits of providing community-based hepatitis C care to people who inject drugs in Australia–benefits that should be realised as direct-acting antiviral agents become available.

16 May 2016 in BMC Infectious Diseases
Verified
Journal Article
Open access
PDF file
AWAmanda J Wade
Amanda J Wade
VVVanessa Veronese
Vanessa Veronese
MHMargaret E. Hellard
Margaret E. Hellard
JDJoseph Doyle
Joseph Doyle
Hepatitis C virus (HCV) treatment uptake globally is low. A barrier to treatment is the necessity to attend specialists, usually in a tertiary hospital. We investigate the literature to assess the effect of providing HCV treatment in the community on treatment uptake and cure. Three databases were searched for studies that contained a comparison between HCV treatment uptake or sustained virologic response (SVR) in a community site and a tertiary site. Treatment was with standard interferon with or without ribavirin, or pegylated interferon and ribavirin. A narrative synthesis was conducted. Thirteen studies fulfilled the inclusion criteria. Six studies measured treatment uptake; three demonstrated an increase in uptake at the community site, two demonstrated similar rates between sites and one demonstrated decreased uptake at the community site. Nine studies measured SVR; four demonstrated higher SVR rates in the community, four demonstrated similar SVR rates, and one demonstrated inferior SVR rates in the community compared to the tertiary site. The data available supports the efficacy of HCV treatment in the community, and the potential for community based treatment to increase treatment uptake. Whilst further studies are required, these findings highlight the potential benefit of providing community based HCV care – benefits that should be realised as interferon-free therapy become available. (PROSPERO registration number CRD42015025505).

16 April 2018 in Journal of Viral Hepatitis
Verified
Journal Article
Closed access
PDF file
AWAmanda J Wade
Amanda J Wade
AMA. McCormack
A. McCormack
CRC. Roder
C. Roder
KMK. McDonald
K. McDonald
MDM. Davies
M. Davies
MHM. E. Hellard
M. E. Hellard

1 April 2018 in Journal of Virus Eradication
Verified
Journal Article
Open access
NSNick Scott
Nick Scott
SHSamuel W. Hainsworth
Samuel W. Hainsworth
RSRachel Sacks-Davis
Rachel Sacks-Davis
APAlisa Pedrana
Alisa Pedrana
JDJoseph Doyle
Joseph Doyle
MHMargaret Hellard
Margaret Hellard
Direct-acting antiviral (DAA) treatments became available for all people living with hepatitis C virus (HCV) in Australia in March 2016. We assess variations in treatment rates and prescribing patterns across Australia's 338 Statistical Area 3 (SA3) geographical units. Geocoded DAA treatment initiation data were analysed for the period 1 March 2016 to 30 June 2017. Regression models tested associations between the population demographics and healthcare service coverage of geographical areas and (a) their treatment rates; and (b) the proportion of prescriptions written by specialists compared to non-specialists. Across the 320 areas (95%) recording treatments, a median 76 (interquartile range [IQR] 35-207, range 4-3834) per 100,000 were initiated, corresponding to an estimated median 7.9% (IQR 2.9-23.6%, range 0-100%) treatment uptake. Major cities, areas of socioeconomic advantage and areas with lower proportions of the population born overseas had the highest per capita treatment rates. Non-specialists prescribed 46% (20,323/44,382) of treatment initiations. Prescriptions were written by non-specialists only in 163 areas (51%), while in other areas a median 40.0% (IQR 21.8-62.5%) of prescriptions were written by non-specialists. Non-specialist prescribing was higher in regional areas, as well as areas that had greater proportions of Indigenous Australians. High national-level treatment uptake of 20% in Australia masks underlying health system limitations; more than half of geographical areas may have treated less than 8% of people living with HCV. Areas of socioeconomic disadvantage and areas with a higher proportion of the population born overseas may need targeting with interventions to improve treatment uptake.

1 April 2017
Verified
Journal Article
Closed access
AWAmanda J Wade
Amanda J Wade
BDBridget Draper
Bridget Draper
JDJoseph Doyle
Joseph Doyle
NANicole Allard
Nicole Allard
PGPaul Grinzi
Paul Grinzi
MHMargaret Hellard
Margaret Hellard

16 July 2018 in Trials
Verified
Journal Article
Open access
PDF file
AWAmanda J Wade
Amanda J Wade
JDJoseph Doyle
Joseph Doyle
EGE. Gane
E. Gane
CSC. Stedman
C. Stedman
BDB. Draper
B. Draper
MHM. E. Hellard
M. E. Hellard
To achieve the World Health Organization hepatitis C virus (HCV) elimination targets, it is essential to increase access to treatment. Direct-acting antiviral (DAA) treatment can be provided in primary healthcare services (PHCS), improving accessibility, and, potentially, retention in care. Here, we describe our protocol for assessing the effectiveness of providing DAAs in PHCS, and the impact on the HCV care cascade. In addition, we reflect on the challenges of conducting a model of care study during a period of unprecedented change in HCV care and treatment. Consenting patients with HCV infection attending 13 PHCS in Australia or New Zealand are randomized to receive DAA treatment at the local tertiary institution (standard care arm), or their PHCS (intervention arm). The primary endpoint is the proportion commenced on DAAs and cured. Treatment providers at the PHCS include: hepatology nurses, primary care practitioners, or, in two sites, a specialist physician. All PHCS offer opioid substitution therapy. The Prime Study is the first real-world, randomized, model of care study exploring the impact of community provision of DAA therapy on HCV-treatment uptake and cure. Although the study has faced challenges unique to this period of time characterized by changing treatment and service delivery, the data gained will be of critical importance in shaping health service policy that enables the elimination of HCV. ClinicalTrials.gov , ID: NCT02555475 . Registered on 15 September 2015.